Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04116502
Title MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polcythemia Vera (MITHRIDATE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors University of Birmingham
Indications

polycythemia vera

Therapies

Ruxolitinib

Hydroxyurea

Alpha 2 Interferon

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST